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a b s t r a c t
Background: Alzheimer's disease (AD) is a devastating condition with no known effective drug treatments.
Existing drugs only alleviate symptoms. Given repeated expensive drug failures, we assessed systematically
whether approved and investigational AD drugs are targeting products of genes strongly associated with AD
and whether these genes are targeted by existing drugs for other indications which could be re-purposed.
Methods: We identiﬁed genes strongly associated with late-onset AD from the loci of genetic variants associated
with AD at genome-wide-signiﬁcance and from a gene-based test applied to the most extensively genotyped
late-onset AD case (n = 17,008)-control (n = 37,154) study, the International Genomics of Alzheimer's Project.
We used three gene-to-drug cross-references, Kyoto Encyclopedia of Genes and Genomes, Drugbank and Drug
Repurposing Hub, to identify genetically validated targets of AD drugs and any existing drugs or nutraceuticals
targeting products of the genes strongly associated with late-onset AD.
Findings: A total of 67 autosomal genes (forming 9 gene clusters) were identiﬁed as strongly associated with lateonset AD, 28 from the loci of single genetic variants, 51 from the gene-based test and 12 by both methods.
Existing approved or investigational AD drugs did not target products of any of these 67 genes. Drugs for other
indications targeted 11 of these genes, including immunosuppressive disease-modifying anti-rheumatic drugs
targeting PTK2B gene products.
Interpretation: Approved and investigational AD drugs are not targeting products of genes strongly associated
with late-onset AD. However, other drugs targeting products of these genes exist and could perhaps be repurposing to combat late-onset AD after further scrutiny.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Alzheimer's disease (AD) has remained incurable since its ﬁrst discovery in 1906 [1]. An estimated one-third of AD cases may be associated with lifestyle or related attributes, education and other health
conditions (hypertension, obesity, diabetes, depression) [2], although
the exact interventions require clariﬁcation [3]. Mendelian randomization studies using single nucleotide polymorphisms (SNPs) as instruments suggest that apolipoprotein E, systolic blood pressure, smoking
and vitamin D are inversely associated with AD [4–6]. Effective therapies to prevent and treat AD were called for globally at the G8 dementia
summit in 2013 [7], because of the escalating societal costs if AD remains untreated [8]. Effective drug treatments for AD have proved
elusive.
Current understanding of AD is based on factors identiﬁed from
brain autopsies, which in 1976 implicated acetylcholine, “the

https://doi.org/10.1016/j.ebiom.2018.10.001
2352-3964/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
We searched PubMed for articles on Alzheimer's disease (AD)
published between January 1, 1960 and August 28, 2018 using
the terms: (“Alzheimer's disease” AND genetics AND GWAS) to
identify AD genes; and (“Alzheimer's disease” AND “drug therapy”)
to identify AD treatments. We screened articles by title and abstract
to locate full-text articles relevant to the study aims, supplemented
by reference lists of the relevant articles. We considered articles that
examined the associations of genetic variants or genes with lateonset AD, or evaluated existing or investigational AD drugs. AD
drug development has encountered limited efficacy of existing
drugs and repeated expensive failures of investigational drugs. Genetic validation of drug targets may provide the impetus to rethink
effective drug treatments for late-onset AD. Genetic variants related
to late-onset AD have been extensively identified from genomewide association studies (GWAS); however, late-onset AD genes,
rather than loci, are less studied. Only two gene-based studies of
late-onset AD have been published. One study in people of
European ancestry found two new genes and one trans-ethnic
study found another new gene. However, none of these genebased studies compared with AD drug targets. Only one study compared genetic loci from previous GWAS with targets of approved
AD drugs and found no overlaps. No studies have considered
whether products of late-onset AD genes are targets of numerous
on-going investigational AD drugs or whether any late-onset AD
gene products are targeted by drugs for other indications.
Added value of this study
We revisited the late-onset AD genes of European ancestry using a
new gene-based association analysis and compared them with
known late-onset AD genes indicated by loci from previous
GWAS. We then compared all these late-onset AD gene products
with targets of currently approved or investigational AD drugs and
identified drugs for other indications targeting any late-onset AD
gene products. This gene-based association analysis of lateonset AD replicated 12 genes found by previous GWAS and additionally identified 39 genes. We did not replicate 3 genes found by
the two previous gene-based studies, perhaps partly due to
population-specific relevance of particular genes. Moreover, this
study found no evidence that approved AD drugs or AD drugs in
Phase III trials are targeting the products of genes strongly associated with late-onset AD, consistent with a previous study comparing AD genetic loci with approved AD drugs, although false
negative findings due to incomplete knowledge remains possible.
Among all 67 late-onset AD genes from this gene-based study and
previous GWAS, 11 genes are targets of other existing drugs,
which could possibly be further scrutinized for appropriate alignment of disease genetics and drug actions before re-purposing.
Implications of all the available evidence
This study forms an initial step in translating genetic evidence to
AD drug development. It also highlights the importance of genetic
validation of investigational AD drugs as an initial screening tool to
identify promising late-onset AD drug.

cholinergic hypothesis” [9,10], and subsequently implicated betaamyloid (Aβ) in extracellular plaques in 1984 and tau proteins in
neuroﬁbrillary tangles in 1986 [11]. Drug development based on

these hypotheses has yielded two types of drugs for AD approved
by the U.S. Food and Drug Administration (FDA), including cholinesterase inhibitors, N-methyl-D -aspartate receptor antagonists, and
the combination of these inhibitors. These drugs relieve symptoms
rather than delaying progression. No new AD drugs have been approved by the U.S. FDA since 2003, despite over 400 trials from
2002 to 2012 mainly targeting Aβ [12]. These difﬁculties may be
due to lack of pre-trial biomarker screening to identify high risk patients as selection criteria [13], or use of subjectively rated cognitive
and functional outcomes rather than validated biomarkers [14].
However, failure of anti-Aβ drugs has raised questions about the
causal role of amyloid protein in AD and the relevance of the amyloid
protein hypothesis to AD drug development [15,16]. In vitro studies
suggest Aβ and its precursor amyloid protein precursor are damage
response proteins [17] so amyloid plaque may be a consequence
rather than a cause [18]. More importantly, both Aβ and tau protein
may not only be neurotoxins, but also be relevant to normal physiological functions [15].
In response to issues with drug development, genetic validation
of drug targets is becoming increasing popular, and has recently explained the failure of several cardiovascular drugs, such as
darapladib and varespladib, where functionally relevant genetic variants were found relevant to the drug but not to the disease [19,20].
However, overall a small number of drug identiﬁed from SNP-based
genome-wide association studies (GWAS) have raised the concerns
that GWAS may fail to identify causal SNPs by excluding SNPs with
greater effect but low frequency [21]. To identify new targets for
the most common form of AD, i.e., late (65+ years)-onset AD
agnostically, we considered genetic variation in naturally occurring
functional units, i.e., genes, as an initial step. A previous gene-based
study of people of European ancestry in the International Genomics
of Alzheimer's Project (IGAP) found 13 genes known from genetic
loci of SNPs identiﬁed in GWAS, 3 genes in close proximity to 2
known genes and 2 new genes (TP53INP1, IGHV1–67) [22]. Another
gene-based study of AD in a trans-ethnic GWAS of people of
European, African-Americans, Japanese and Israeli-Arabs ancestry
replicated 7 known genes and identiﬁed 1 new gene (TPBG) [23].
However, these studies did not compare late-onset AD gene products
with targets of AD drugs. To our knowledge, only one previous study
has compared AD genetic loci with targets of approved AD drugs
[21]. Here, we build on this previous work by ﬁrstly identifying
genes associated with speciﬁcally late-onset AD from a gene-based
test and from the loci of SNPs found in previous GWAS, secondly
assessing the overlap between these late-onset AD gene products
and targets of currently approved or investigational AD drugs, and
thirdly identifying any other existing drugs or nutraceuticals
targeting products of these late-onset AD genes that could potentially be re-purposed to prevent or treat AD. Given genes from
GWAS have been shown to be more likely to be drug targets than
random genes for complex traits [24] or heritable diseases [25], our
ﬁndings of any discrepancy between products of these AD genes
and drug targets would indicate opportunities for using AD genes
for drug discovery and repurposing. Conversely, genes without
even a nominal association with late-onset AD might be screened
out and de-prioritized as indicators of potential targets of
intervention.
2. Materials and methods
2.1. Genes associated with AD
We obtained genes strongly associated with late-onset AD using
two approaches. First, we ascertained AD genes from all loci of single
nucleotide polymorphisms (SNPs) associated with late-onset AD at
genome wide signiﬁcance in a recent review of GWAS [26]
(i.e., SNP-based GWAS). In addition, we did not use the Online
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Mendelian Inheritance in Man (OMIM) because no additional genes
associated with late-onset AD reaching genome-wide Bonferroni
corrected signiﬁcance could be identiﬁed. Second, we ascertained
AD genes as genes associated with AD at Bonferroni corrected significance using a gene-based test applied to the largest, most densely
genotyped (7,055,881 SNPs genotyped or imputed in autosomal
chromosomes using the 1000 Genomes catalog) case (n = 17,008)control (n = 37,154) study of AD, stage 1 discovery sample from
the IGAP, in people of European descent (mean age 71.4 years) adjusted for age and sex and corrected for population stratiﬁcation
[27]. Among all these late-onset AD genes, we then obtained gene
clusters based on two or more genes that encode for similar proteins
within the same gene family classiﬁed by the HUGO Gene Nomenclature Committee (HGNC) [28].
2.2. Therapies targeting identiﬁed genes
To assess whether existing AD drugs are targeting products of
late-onset AD genes and whether genes strongly associated with
AD are being fully exploited, two researchers independently identiﬁed the genes targeted by AD drugs using three gene-to-drug
cross-references, Kyoto Encyclopedia of Genes and Genomes
(KEGG) [29], Drugbank [30], and Drug Repurposing Hub [31] as of
August 30, 2018. For existing AD drugs, in KEGG, we searched each
drug on “KEGG Drug” and identiﬁed the targets given in the “Target
pathway”. In Drugbank, we searched for each drug by specifying
“Drugs”, and identiﬁed the targets based on “Targets: Gene Name”.
In Drug Repurposing Hub, we searched each drug by specifying
“Name:” and identiﬁed the targets based on the “Target”. To identify
treatments targeting AD genes, in KEGG, we searched each gene on
“KEGG Disease” and identiﬁed the treatments for that particular
gene as listed in “Gene” given in the “Drug target”. In Drugbank, we
searched for each gene by specifying “Targets”, and identiﬁed the
treatments based on “Drug relations” (including drugs labeled as
“approved” with known pharmacological action). In Drug
Repurposing Hub, we searched each gene by specifying “Target:”
and identiﬁed the treatments based on the “Name” (including
drugs labeled as “Launched” phase). We considered all existing or investigational AD drugs. The list of investigational drugs was based on
drugs being tested in recruiting or active Phase III or IV trials registered in ClinicalTrial.gov or listed in AlzForum (http://www.
alzforum.org/therapeutics) as of January 28, 2018, supplemented
by drugs in Phase III trials listed in Cummings J, et al. (2016) [32], excluding diagnostic drugs and drugs for sequelae of AD, such as for agitation or sleep disorders.
2.3. Statistical analysis
We obtained an overall P-value for the association of each autosomal
gene with late-onset AD by combining P-values for the association of all
the SNPs within each gene using GATES accounted for linkage disequilibrium between loci [33]. GATES has the advantage of not requiring
permutations or simulations, and maintains a Type I error (false positive) rate regardless of gene size or linkage disequilibrium patterns
among SNPs. We only considered genes reaching genome-wide
Bonferroni corrected signiﬁcance (nominal P-valueb.000002, i.e., .05/
25000 genes) such that genes identiﬁed from this gene-based test are
selected on the same basis as genes identiﬁed from SNP-based GWAS
[26]. We performed a hypergeometric test to obtain the probability of
the identiﬁed genes being targeted by AD drug or drugs for other indications, assuming 5% of the human genomes (same as the signiﬁcance
level of one-tailed Fisher test) are targeted by AD drugs or drugs for
other indications (n = 1250 genes) and the remaining genes are not
targeted. This analysis of publicly available data does not require ethical
approval.
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3. Results
Table 1 shows that 28 genes strongly associated with AD were
identiﬁed from the SNP-based GWAS [26] and 51 from the genebased test, with 12 genes (APOE, CLU, BIN1, CR1, PICALM, MS4A6A,
EPHA1, SORL1, ABCA7, PTK2B, CD33, CD2AP) identiﬁed by both approaches. A total of 16 genes (SLC24A4-RIN3, CELF1, CASS4, TRIP4,
ZCWPW1, HLA-DRB5-HLA-DRB1, FERMT2, NME8, INPP5D, TREM2,
TREML2, MEF2C, ACE, APP, PLD3, DSG2) were only identiﬁed from
the SNP-based GWAS, and 39 genes (including 2 pseudogenes:
APOC1P1, CEACAM22P) were only identiﬁed from the gene-based
test. Most of these 67 genes (n = 33) were on chromosome 19,
where all 4 genes with the smallest P-value (APOC1, APOE, NECTIN2,
TOMM40) are located. When considering these 67 genes together, 9
gene clusters were identiﬁed including apolipoproteins (APOC1,
APOE, APOC2, APOC4, APOC4-APOC2), carcinoembryonic antigen related cell adhesion molecule (CEACAM16, CEACAM19), cluster of differentiation molecule (ACE, CD33, CD2AP), complement system (CR1,
CR1L), ephrins (EPHA1, EPHA1-AS1), histocompatibility complex
(HLA-DQA1, HLA-DRB5-HLA-DRB1), membrane spanning 4-domains
(MS4A6E, MS4A4A, MS4A6A, MS4A4E, MS4A2), microRNAs
(MIR6843, MIR6503, MIR4531) and V-set domain containing
(TREM2, TREML2). As such, in addition to identifying the same 12
genes and 7 gene clusters as previous SNP-based GWAS, this genebased test newly identiﬁed 39 genes (of which 4 genes were in
strong linkage disequilibrium with previously known genes) and 2
gene clusters (CEACAM, MIR) (formed from 5 genes).
The current approved or investigational AD drugs did not target
products of any of these 67 genes strongly associated with AD
(Table 2). However, drugs for other indications targeted products
of 11 of the 67 late-onset AD genes, with P-value = .0001 which indicates our results unlikely occurred by chance. These other drugs
targeting products of these 11 genes (ACE, APP, APOE, CD33, CLU,
EPHA1, HBEGF, HLA-DQA1, HLA-DRB1, MS4A2, PTK2B) including
Gemtuzumab ozogamicin which targets CD33 gene products,
Omalizumab which targets MS4A2 gene products and Baricitinib/
Fostamatinib/Leﬂunomide which targets PTK2B gene products
(Table 3).

4. Discussion
Among the 67 genes found strongly associated with late-onset AD,
this gene-based study replicated 12 genes and 7 gene clusters found
by previous SNP-based GWAS and identiﬁed 39 new genes (of which
4 genes were in strong linkage disequilibrium with previously known
genes) and 2 new gene clusters (formed from 5 genes). However, we
did not replicate 3 genes (TP53INP1, IGHV1–67, TPBG) found by previous
gene-based studies, possibly because the study of people of European
ancestry in IGAP used Fisher's combination test [22], which is prone to
type 1 error [33], and the trans-ethnic GWAS using the same GATES
method may have identiﬁed population-speciﬁc genes [23]. Moreover,
our study suggests existing AD drugs (cholinesterase inhibitors or Nmethyl-D-aspartate receptor antagonists) may not be targeting products of these late-onset AD genes, consistent with the previous comparison of AD genetic loci with approved AD drugs [21]. We also found that
existing investigational AD drugs currently in Phase III trials (anti-Aβ
agents, anti-tau agents, other neurotransmitters agonist/antagonists
and insulin sensitizers) did not appear to be targeting products of
late-onset AD genes. We cannot rule out the possibility that incomplete
knowledge of AD genes and/or drug targets could generate such null
ﬁndings. Finally, we found products of 11 AD genes are targets of
existing drugs for other indications, which could possibly be considered
for further scrutiny of directionality of disease genetics and drug actions
within an integrated biological networks before re-purposing to mitigate or cure late-onset AD.
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Table 1
Genes associated with late-onset Alzheimer's diseasea identiﬁed from gene-based association test and/or single nucleotide polymorphism (SNP)-based genome-wide association studies
(GWAS).
Chromosome

Gene-based test + SNP-based GWAS

Gene-based testb

Position

Position

P-value
−13

SNP-based GWAS

Gene

P-value

CR1L

3.01 × 10

1.76 × 10−06

139,712,427
32,605,182

HBEGF
HLA-DQA1

1.83 × 10−06
9.36 × 10−07

EPHA1

7.57 × 10−10

143,104,905

EPHA1-AS1

1.92 × 10−09

CLU
PTK2B
PICALM
MS4A6A
SORL1

5.91 × 10−16
3.66 × 10−07
9.31 × 10−11
6.24 × 10−10
5.25 × 10−09

27,468,117

MIR6843

6.39 × 10−16

60,102,354
60,048,013
59,968,725
59,976,543
59,856,136

MS4A6E
MS4A4A
MS4A4E
MIR6503
MS4A2

9.71 × 10−12
1.04 × 10−10
1.59 × 10−09
1.76 × 10−09
4.47 × 10−09

CR1
BIN1

47,445,524

CD2AP

7

143,088,204

8

27,454,433
27,183,080
85,668,213
59,939,970
121,322,911

2.25 × 10
2.86 × 10−14

14
15
17
18
19

45,409,657
1,040,101
51,728,334

APOE
ABCA7
CD33

0
2.12 × 10−07
8.09 × 10−07

45,417,811
45,430,059
45,349,392
45,394,476
45,312,315
45,281,125
45,251,977
45,653,007
45,458,480
45,596,430
45,666,185
45,682,002
45,504,706
45,449,238
45,542,297
45,445,494
45,445,494
45,715,634
45,147,097
45,588,586
45,583,162
45,202,420
45,174,723
45,156,955
45,116,939
1,076,632
45,041,044
46,213,886
46,236,508

APOC1
APOC1P1
NECTIN2
TOMM40
BCAM
CBLC
BCL3
NKPD1
CLPTM1
PPP1R37
TRAPPC6A
BLOC1S3
RELB
APOC2
CLASRP
APOC4
APOC4-APOC2
EXOC3L2
PVR
LOC105372419
GEMIN7
CEACAM16
CEACAM19
MIR4531
IGSF23
ARHGAP45
CEACAM22P
FBXO46
BHMG1

20
21

Position

Gene

P-value

234,068,476
88,223,420
32,578,530
41,129,252
41,154,650
100,004,446
37,841,534

INPP5D
MEF2C
HLA-DRB5-HLA-DRB1
TREM2
TREML2
ZCWPW1
NME8

1.21 × 10−03
0.01
8.77 × 10−05
5.09 × 10−03
9.98 × 10−03
8.56 × 10−05
3.70 × 10−04

47,557,871

CELF1

2.90 × 10−05

92,926,952
53,400,629
64,725,490
61,538,148
29,088,958
40,877,595

SLC24A4-RIN3
FERMT2
TRIP4
ACE
DSG2
PLD3

6.71 × 10−06
3.50 × 10−04
4.79 × 10−05
0.01
0.98
0.90

55,018,260
27,269,932

CASS4
APP

3.60 × 10−05
0.08

−08

207,818,457

1
2
5
6

11

207,669,472
127,805,598

Gene

0
0
0
0
7.50 × 10−68
3.09 × 10−42
9.04 × 10−42
5.26 × 10−20
5.75 × 10−20
8.07 × 10−20
2.78 × 10−18
2.78 × 10−17
5.31 × 10−17
6.67 × 10−16
1.13 × 10−15
2.91 × 10−15
3.38 × 10−15
9.26 × 10−14
2.53 × 10−12
9.04 × 10−12
1.17 × 10−11
3.97 × 10−11
1.58 × 10−09
3.97 × 10−09
4.25 × 10−08
8.21 × 10−08
9.34 × 10−08
1.23 × 10−06
1.30 × 10−06

Abbreviations: GWAS: genome wide association studies; SNPs: single nucleotide polymorphisms.
a
All gene P-values were based on gene-based association test.
b
Among the 39 genes newly identiﬁed from the gene-based test, 4 genes were in strong linkage disequilibrium with previously known genes (previous gene vs. new gene with r2: CLU
vs. MIR6843 (0.875); MS4A6A vs. MS4A2 (0.844); MS4A6A vs. MIR6503 (0.844) and ABCA7 vs. ARHGAP45 (0.967).

Our study suggests a ‘mismatch’ between approved or investigational AD drugs and the genes strongly related to late-onset AD.
Cholinesterase inhibitors are not the only neurotransmitter related
to AD [11] and may have missed the window of intervention in
late-onset AD because of the accumulated loss of neurological functions [13]. N-methyl- D -aspartate receptor antagonists aim to oppose the effects of the excitatory neurotransmitter glutamate
[34], however the causal role of glutamate in AD is yet to be elucidated [35]. The investigational drugs are mainly anti-Aβ and antitau agents, which are not known to target products of genes associated with late-onset AD, but are largely based on causal

associations with familial AD. Aβ is the product of the APP gene
which is primarily associated with early-onset AD [36] except for
a rare genetic variant [37]. The latest failures of these drug classes
in late-onset AD [38,39], have raised questions as to whether Aβ
and tau proteins are biomarkers [15] or underlying causal targets
[18]. The exact reasons for such an exceptionally high failure rate
remains elusive, but several explanations have been proposed including: anti-Aβ trials have not reported changes in cerebrospinal
ﬂuid Aβ [40], results from animal models may not be comparable
to human trials [41], clearance of existing Aβ protein may be as important as reduction in Aβ generation [42], and off-target pathways
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Table 2
Genes with products targeteda by approved or investigational Alzheimer's disease drugsb.
Type

Drug

Target Gene

Gene
P-value

Class

Approved drugs

Donepezil

ACHE
HTR2A
ACHE
BCHE
ACHE
CHRNA1-A8;A10
CHRNB1-B4
CHRND
CHRNE
CHRNG
BCHE
CHRNA7
CYP2E1
DRD2
GRIN1
GRIN2A/2B
GRIN3A
HTR3A
Nil
ASIC1
BCL2
CFTR
FABP2
KCNMA1
S100P
SLC15A1/A8
PLAT
PPARA
PPARG
PTGS1/2
THBD
AGER

0.65
0.03
0.65
0.73
0.65
0.22
0.77
0.89
0.0003
0.58
0.73
0.72
0.94
0.23
0.97
0.50
0.85
0.24
–
0.28
0.56
0.98
0.99
0.59
0.22
0.40
0.57
0.97
0.98
0.43
0.44
0.13

Acetylcholinesterase inhibitor

Nil
Nil
Nil
Nil
Nil
INS
PPARA
PPARD
PPARG
TRPM3
MAOB
Nil
Nil
Nil
BACE1
ADRA2A-2C
CYP3A5
HCN1/4
INSR
IGF1R
RB1
CTSD
IDE
PCSK1/2
CPE
NOV
LRP2
IGFBP7
SYTL4
Nil
Nil
PPARA
PPARG
RXRA
RXRB
RXRG
SREBF1
Nil
GSK3B
IMPA1/2
GRIA3

–
–
–
–
–
0.97
0.97
0.50
0.72
0.27
-–
–
–
–
0.16
0.38
0.62
0.83
0.78
0.26
0.11
0.45
0.41
0.09
0.30
0.40
0.70
-–
–
0.97
0.72
0.25
0.86
0.13
0.58
–
0.98
0.04
--

Rivastigmine
Galantamine

Memantine

Investigational drugs

Aducanumab
ALZT-OP1a/b

Azeliragon
CNP520
Crenezumab
Elenbecestat
Gantenerumab
JNJ-54861911
Pioglitazone

Intepirdine
Solanezumab
TRx0237
Verubecestat
Guanfacine

Insulin
(Humulin®RU-10)

Lanabecestat
Sodium oligomannurarate
Docosahexaenoic acid

Tricaprilin
Lithium Carbonate

Acetylcholinesterase inhibitor
Acetylcholinesterase inhibitor

N-methyl-D-aspartate receptor antagonist

Anti-amyloid
Anti-amyloid
Anti-inﬂammation

Anti-amyloid
Anti-inﬂammation
Anti-amyloid
Anti-amyloid
Anti-amyloid
Anti-amyloid
Anti-amyloid
Insulin sensitizer
Anti-inﬂammation

Other neurotransmitters (Selective serotonin 5-HT₆ receptor antagonist)
Anti-amyloid
Anti-tau
Anti-amyloid
Other neurotransmitters (Attention Deﬁcit Hyperactivity Disorder drug)

Intranasal insulin

Anti-amyloid
Anti-amyloid (Oligosaccharide)
Other (Unsaturated fatty acid synthesis)

Other (triacylglycerols)
Other (alkali metal compounds)

(continued on next page)
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Table 2 (continued)
Type

Drug

Target Gene

Gene
P-value

Class

Resveratrol

NQO2
CSNK2A1
PTGS1/2
ALOX5/15
AHR
PI4K2B
ITGA5
ITGB3
APP
ESR1
MTNR1A/1B
CLEC14A
NR1I2/3
SLC2A1
SNCA
CBR1
PPARA
PPARG
AKT1
KHSRP
YARS
APOA1
BACE1
SCN5A
SIRT1
TXNRD1/D2
XDH
MAOA
Nil
AGTR1
CACNA1B/1C
CACNA1D/1S
CACNA2D1/D3
CACNB1/B2
CA1
SMPD1
GM2A
SLC6A2
PLA2G2A
GLRA1
GABRA1
GABRB2
GABRG2
Nil

0.97
0.29
0.43
0.06
0.75
0.99
0.44
0.51
0.08
0.13
0.20
0.93
0.16
0.77
0.91
0.67
0.97
0.72
0.26
0.64
0.91
0.27
0.25
0.82
0.71
0.75
0.56
-–
0.97
0.83
0.03
0.98
0.05
0.35
0.96
0.63
0.06
0.90
0.57
0.45
0.81
0.96
–

Anti-inﬂammation (herpes simplex virus)

Acetyl-L-Carnitine
Angiotensin II receptor blocker +
calcium channel blocker

Choline alfoscerate
Ginkgo biloba

Octohydroaminoacridine Succinate

Other (fatty acyls)
Anti-hypertensives

Other (glycerophosphocholines)
Other (possibly improving blood ﬂow)

Acetylcholinesterase inhibitor

a

Source: Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/), Drugbank (https://www.drugbank.ca/) and Drug Repurposing Hub (https://clue.io/
repurposing) as of August 30, 2018.
b
Source: ClinicalTrial.gov (https://clinicaltrials.gov/), Cummings J, et al. (2016) Alzheimer's & Dementia: Translational Research & Clinical Interventions (http://www.trci.alzdem.com/
article/S2352-8737(16)30019-1/pdf) and AlzForum (http://www.alzforum.org/therapeutics). The list of investigational drugs was based on drugs being tested in recruiting or active Phase
III or IV trials registered in ClinicalTrial.gov or listed in AlzForum as of January 28, 2018, supplemented by drugs in Phase III trials listed in Cummings J, et al. (2016), excluding diagnostic
drugs and drugs for sequelae of AD, such as for agitation or sleep disorders.

that induce adverse effects might negate the possible beneﬁts of Aβ
accumulation. Notably, the possibility of citation bias in favour of
the beta-amyloid hypothesis for AD has been raised [43].
We identiﬁed 67 genes strongly associated with late-onset AD
(12 genes from both approaches, 16 from SNP-based GWAS and 39
from the gene-based test). The 12 genes identiﬁed by both approaches relate to lipid metabolism or transport (e.g. APOE, SORL1,
ABCA7), synaptic function (BIN1, PICALM, MA4A6A, PTK2B), immune
response (CR1, CD33, CD2AP) or cell proliferation or apoptosis (CLU,
EPHA1) [44]. With replication by the gene-based test of ﬁndings
from previous SNP-based GWAS, products of these 12 genes could
possibly be potential drug targets. Conversely, 16 genes inferred
from previous SNP-based GWAS as associated with late-onset AD
were not associated with AD on the gene-based test, perhaps indicating that these SNPs might not indicate causal genes [27]. As such,
considering genetic variants in functional units, i.e., genes, as here
may be informative, in addition to considering single genetic variants. For genes with variants representing loss-of-function, drugs

that activate (agonists) proteins in human cells would be needed,
whereas drugs that inhibit (antagonists) would be needed for variants representing gain-of-function [25]. Understanding AD pathogenesis and drug actions are necessary for translating our genetic
validations into identiﬁcation of therapeutic targets.
Other identiﬁed genes, if substantiated by future studies with
clearly deﬁned disease genetics and drug actions, could provide
new, promising directions for late-onset AD therapeutic investigation. For example, NECTIN2 relates to cell-to-cell spreading of the
herpes simplex virus and pseudorabies virus, when herpes simplex
virus type 1 is thought to play a role in AD [45]. A recent drug trial
targeting the virus (VALZ-PILOT) has been launched, although it is
not known to target products of the 67 identiﬁed late-onset AD
genes [46]. Further, the 9 gene clusters identiﬁed by the genebased test and/or SNP-based GWAS could be potentially relevant
genetic loci implicated in late-onset AD. The APO gene cluster (lipoprotein metabolism) consistently identiﬁed by both approaches
may play a causal role. Particularly the APOE gene, as substantiated
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Table 3
Genes strongly associated with late-onset Alzheimer's disease with products targeted by
existing drugsa.
Drug

Target
Gene

Gene
P-value

Class

Afatinib

HBEGF

1.83 × 10−06

Anti-cancer EGFR
inhibitors

Brigatinib
Cetuximab
Erlotinib
Geﬁtinib
Lapatinib
Necitumumab
Neratinib
Olmutinib
Osimertinib
Panitumumab
Glatiramer acetate

HLA-DQA1

9.36 × 10−07

Apolizumab

HLA-DRB1

8.77 × 10−05

Vandetanib

EPHA1

7.57 × 10−10

Copper
Zinc
Zinc acetate
Zinc chloride
Baricitinib

CLU

5.91 × 10−16

Immunomodulator for
multiple sclerosis
Anti-cancer
immunomodulator
Anti-thyroid cancer
EGFR, RET tyrosine,
VEGFR kinase inhibitors
Metal compounds

PTK2B

3.66 × 10−07

Anti-Rheumatoid JAK
inhibitor

Leﬂunomide
Omalizumab

MS4A2

4.47 × 10−09

Alacepril

ACE

0.01

Anti-IgE for severe
allergic asthma
Anti-hypertensive ACE
inhibitors

APOE

0

Metal compounds

CD33

8.09 × 10−07

APP

0.08

Treatment for acute
myleoid leukemia
Nutraceuticals extracted
from tumeric

Benazepril
Benazeprilat
Captopril
Ceronapril
Cilazapril
Delapril
Deserpidine
Enalapril
Enalaprilat
Fosinopril
Fosinoprilat
Gemopatrilat
Imidapril
Indolapril hydrochloride
Libenzapril
Lisinopril
Moexipril
Pentopril
Perindopril
Pivopril
Quinapril
Quinaprilat
Ramipril
Rescinnamine
Spirapril
Spiraprilat
Temocapril
Trandolapril
Zofenopril
Zofenoprilat arginine
Copper
Zinc
Zinc acetate
Zinc chloride
Gemtuzumab ozogamicin
Curcumin

a
Source: Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/
kegg/), Drugbank (https://www.drugbank.ca/) and Drug Repurposing Hub (https://clue.
io/repurposing) as of August 30, 2018.
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by a Mendelian randomization study on apolipoprotein E [4], which
has long been considered as a drug target [47]. Recently, APOE ε4 alleles have been shown to promote a gain of toxic effects by independently promoting Aβ and tau protein production in human neurons
[41]. Taken together with the null ﬁndings from randomized controlled trials of statin on cognitive functions [48] and Mendelian
randomization studies of low-density lipoprotein cholesterol [49]
and triglyceride [50] on late-onset AD, better understanding on
the functionality of both gene and gene clusters would add more
nuanced mechanistic insights on lipid metabolism e.g. apolipoprotein E as a cholesterol transport protein may be more relevant
than cholesterol synthesizing proteins.
Importantly, this study identiﬁed products of 11 late-onset AD
genes that are currently targeted by other therapies [51–53] that
could possibly be further investigated to clarify the disease genetics
and drug actions before repurposing for late-onset AD. Gemtuzumab
ozogamicin, which targets CD33 gene products, is an approved treatment for acute myeloid leukemia and has been considered for repurposing in AD [54]. Omalizumab, which targets MS4A2 gene products and another gene (FCER1A), is a subcutaneous injectable controlling moderate-to-severe allergic asthma; Leﬂunomide, which
targets PTK2B gene products in addition to 2 other genes (AHR,
PTK2B), is an orally-administered immunosuppressive diseasemodifying anti-rheumatic drug. These existing drugs already have
phase II trial results such that pharmacodynamics, pharmacokinetics, toxicity, preclinical effects in vitro and in vivo and phase I safety
and dosage results are known, which reduces the risk, time and resources needed for possible drug re-purposing after more scrutiny
of their relevance to AD.
Our ﬁndings provide an initial step in translating AD genetics to
therapeutic targets and should be enriched using network medicine
by characterizing any drug actions within biological networks.
Given many diseases including late-onset AD may be related to
functional disruption of multiple genes rather than single genes
and these genes may cluster and interact as disease modules, network medicine may help integrate regulatory networks, RNA networks, protein-protein interactions and metabolic pathways to
delineate the complex links from disease genes to drug targets
[55]. Moreover, disease proximity and similarity between two different drugs might indicate shared mechanisms between two diseases with implications for drug re-purposing [56]. Drugs may
target speciﬁc but not entire disease modules [56] and may partly
inhibit or activate interactions and functions [57], thereby AD
drug targets are not necessarily the products of AD genes. In addition, only a fraction of proteins (gene products) can be manipulated
by small molecule drugs [57]. Clarifying the direction of drug actions as well as the drug effects within integrated biological networks would help identify gene products as druggable targets. As
such, building and integrating drug-drug relationships, geneprotein interactions, and disease-disease networks may provide a
framework for further identifying drug targets [58]. Further, the
use of computational drug-target interactions may help predict
druggability by integrating genomics, pharmacological properties,
biochemical interactions supplemented with similarities between
drugs and target proteins [59]. Although the network-based analytical techniques are evolving and the interactome and drug-protein
interactions remain to be fully understood, to date, network-based
analysis using GWAS data has contributed in prioritizing disease
genes by mapping candidate genes within the protein-protein interaction network [60] supplemented by further searches of subnetworks [61]. Speciﬁcally for AD, Talwar et al. (2014) found 6
gene clusters related to 7 proteins encoded by genes EGFR, ACTB,
CDC2, IRAK1, APOE, ABCA1, AMPH with EGFR and ACTB as key genes
[62]. Browne et al. (2015) found 32 prioritized AD genes with
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PSEN1 and TRAF1 as key genes [63]. Both studies identiﬁed AD genes
primarily related to neurogenesis and its regulation based on functional annotation using gene-ontology [62,63]. Hu et al. (2017)
found 3 main modules related to neuronal pathways and metabolism, cell growth or survival and neuroendocrine, and immune response using pathway crosstalk analysis [64]. Given these
previous studies only considered AD genes as a whole, our systematically identiﬁed late-onset AD genes could be utilized for lateonset AD-related gene cluster identiﬁcation and functional annotation. Mostafavi et al. (2018) found INPPL1 and PLXNB1 related to
late-onset AD using RNA sequencing from a cohort of 478 older
adults with brain autopsy [65]. While these previous networkbased studies do not replicate in their most relevant genes, two of
these genes (ABCA1, INPPL1) are paralog of genes identiﬁed in our
study (ABCA7, INPPD5). Alternatively, comparison of gene expression proﬁles and drug-induced RNA expression proﬁles could provide further insights to connect genes to existing drugs [66,67].
Issa et al. (2016) found several approved or experimental drugs
(such as Rasagiline, Interferons, Calcium, Dovitinib, Somatropin Recombinant) related to AD [68]. Vargas et al. (2018) found 6 approved drugs (Cefuroxime, Cyproterone, Dydrogesterone,
Metrizamide, Trimethadione, Vorinostat) negatively associated
with AD [69]. Both studies used disease-related gene expression
from the Gene Expression Omnibus (GEO) database, but applied to
different drug-induced expression proﬁles, which might account
for the differences in the identiﬁed drugs [68,69]. The late-onset
AD genes and existing drugs for other indications identiﬁed in this
study would allow more reﬁned comparison of expression proﬁles
in future studies for drug repurposing, of which timely evidence is
needed considering this study identiﬁed that current approved
and investigational AD drugs may not be targeting late-onset AD
genes.
This systematic and agnostic identiﬁcation of genes for late-onset
AD provides directions for re-thinking AD treatments. Nevertheless,
several limitations are noted. First, the genes identiﬁed here from
IGAP relate to late-onset AD. As such, they may not be relevant to
early-onset AD, i.e., AD occurring before the age of 65 years, which
may explain the non-identiﬁcation of the 3 genes (APP, PSEN1,
PSEN2) associated with early-onset AD [36]. Although a rare variant
of APP might be related to late-onset AD as well, but is likely
context-speciﬁc as it has been found in Nordic countries whereas it
is very rare in the United States [37]. Second, the genes identiﬁed
might not be a complete set and did not include genes on the sex
chromosomes. Replication of the gene-based test in a different population or using a future GWAS with a larger sample size may reveal
additional genetic targets. The recent trans-ethnic GWAS for AD
using a gene-based test with the same GATES method identiﬁed 8
late-onset AD genes, of which nearly all genes (CR1, BIN1, PTK2B,
CLU, PICALM, and ABCA7) were also identiﬁed in our study. The only
new gene (TPBG) that study identiﬁed was neither found in the previous GWAS of European ancestry [26] nor reached genome-wide
signiﬁcance in their European ancestry-speciﬁc result [23], indicating the relevance of certain genes may be population-speciﬁc. Nevertheless, consistency in genes identiﬁed in both trans-ethnic GWAS
and our study with a larger sample size and greater power without
excluding SNPs with P-valueb1 × 10−5 lends credence to the genebased association approach. Third, this study aims to identify potential genetically validated drug targets rather than map out the full genetic functionality or pathophysiology of these targets, because repurposing therapies acting on genetically validated targets may be
the swiftest way of developing effective new treatments. We acknowledge that the current gene-based analysis might not provide
comprehensive therapeutic effects and AD pathogenesis. Comparing
disease gene-related and drug-induced gene expression proﬁles may
provide further insights [66]. Fourth, our identiﬁed drug targets depend on the validity and completeness of KEGG, Drugbank and

Drug Repurposing Hub. While the Drug Repurposing Hub incorporates extensive in-house drug target data, more publicly available
data from pharmaceutical companies would make the search more
comprehensive especially for investigational drugs [70]. Moreover,
these curated cross-references are constantly being made more comprehensive to reﬂect new discoveries, so it is possible that new targets will be found in the future. Fifth, some valid targets of existing
drugs might not reach genome wide signiﬁcance. For example the
gene related to statins (HMGCR) [71] is only nominally (P-value =
.004) associated with ischemic heart disease [72]. Sixth, the genebased test considers SNPs within or near the genes using the same
amount of SNPs as the SNP-based GWAS, but not intergenic regions
[33]. Our ﬁndings can be supplemented by future studies identifying
SNPs outside of genes associated with late-onset AD to provide a
comprehensive AD genome. Seventh, this study considers genes reported based on index SNPs to allow comparison with previous AD
GWAS [26]. However, SNP-based GWAS identiﬁes genomic regions
(loci) which may correspond to multiple genes that do not necessarily correspond to the genes implicated in late-onset AD [73]. Consideration of multiple genes within the loci given in a recent review of
GWAS of late-onset AD [73] identiﬁed 4 more genes (HLA-DQA1,
MS4A4A, MS4A6E, MS4A2) using both approaches. Our gene based
test identiﬁed 35 genes not found by previous SNP-based GWAS. Finally, case-control studies of older people are inevitably open to selection bias, meaning that genes lethal for other diseases may
appear relevant to late-onset diseases [74]. However, the genes we
identiﬁed are not associated with major diseases that may result in
death before the onset of AD, such as ischemic heart disease [72] or
stroke [75].
In conclusion, our study provides no evidence that approved and investigational AD drugs are targeting products of genes strongly associated with late-onset AD, which might explain the lack of efﬁcacy to
date. Genetic validation of potential AD drugs might help to identify
the most promising drugs to try to combat AD, conversely a genebased test may also provide an initial screening tool to identify drugs
that are unlikely to be successful. Other drugs targeting products of
late-onset AD genes do already exist, but the mechanisms of disease genetics and drug actions need further clariﬁcation before proposing drug
targets to combat late-onset AD.
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